 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Nov 27, 2012
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
- ||| REGN1400 / Regeneron
New P1 trial, Combination therapy: Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer (clinicaltrials.gov) - Nov 14, 2012
P1, N=59, Recruiting, Sponsor: Regeneron Pharmaceuticals
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Nov 14, 2012
P2, N=39, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1/2 data, Enrollment change, Combination therapy, Surgery, Metastases: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer (clinicaltrials.gov) - Nov 5, 2012
P1/2, N=23, Completed, Sponsor: George Albert Fisher
Recruiting --> Completed N=60 --> 23
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment closed, Combination therapy: Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Nov 5, 2012
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 23 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 31, 2012
P1, N=19, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=29 --> 19
- ||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
New P1/2 trial, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 30, 2012
P1/2, N=124, Recruiting, Sponsor: Novartis Pharmaceuticals
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P1, N=24, Terminated, Sponsor: Southwest Oncology Group
N=29 --> 19 Active, not recruiting --> Terminated; Study closed early due to poor accrual.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P1, N=24, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Terminated; Study closed early due to poor accrual. N=75 --> 24
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Monotherapy, Metastases: SAKK 41/10: Cetuximab for Elderly Patients With mCRC (clinicaltrials.gov) - Oct 29, 2012
P2, N=78, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=242, Completed, Sponsor: Southwest Oncology Group
N=75 --> 24 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Oct 25, 2012
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial initiation date, Metastases: Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib (clinicaltrials.gov) - Oct 23, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Initiation date: Sep 2012 --> Dec 2012
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=61, Completed, Sponsor: Jiangsu Cancer Institute & Hospital
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: FIRE-3: 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) (clinicaltrials.gov) - Oct 21, 2012
P3, N=568, Active, not recruiting, Sponsor: PD Dr. med. Volker Heinemann
Initiation date: Sep 2012 --> Dec 2012 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver (clinicaltrials.gov) - Oct 17, 2012
P1, N=140, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=108 --> 140
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2012
P2, N=72, Completed, Sponsor: Bristol-Myers Squibb
N=108 --> 140 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=42, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Oct 9, 2012
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2 trial, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 8, 2012
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Combination therapy: AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer (clinicaltrials.gov) - Oct 4, 2012
P1, N=10, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=15 --> 10
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Metastases: Anti-EGFR Immunoliposomes in Solid Tumors (clinicaltrials.gov) - Oct 3, 2012
P1, N=26, Completed, Sponsor: University Hospital, Basel, Switzerland
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Caprelsa (vandetanib) / Sanofi
Trial completion, Metastases: ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 2, 2012
P1, N=46, Completed, Sponsor: Dana-Farber Cancer Institute
N=15 --> 10 Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P2 trial, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 30, 2012
P2, N=76, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study in Advanced Solid Tumors (clinicaltrials.gov) - Sep 24, 2012
P2, N=15, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed N=30 --> 15
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Study in Advanced Solid Tumors (clinicaltrials.gov) - Sep 24, 2012
P2, N=15, Recruiting, Sponsor: Eli Lilly and Company
N=30 --> 15 N=30 --> 15
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
HEOR: Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=50, Recruiting, Sponsor: National Center for Tumor Diseases, Heidelberg
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX (clinicaltrials.gov) - Sep 23, 2012
P2, N=20, Recruiting, Sponsor: Mohammed Almubarak, MD
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Biomarker, FDG PET, Metastases: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=25, Recruiting, Sponsor: VU University Medical Center
- || imgatuzumab (RO5083945) / Centessa
Enrollment change: A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 18, 2012
P1, N=62, Completed, Sponsor: Hoffmann-La Roche
N=30 --> 15 N=6262 --> 62
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: BALI-1: Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (clinicaltrials.gov) - Sep 6, 2012
P2, N=181, Completed, Sponsor: Merck KGaA
N=6262 --> 62 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: CALGB/SWOG 80405: Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 5, 2012
P3, N=2900, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery, Metastases: ECKINOXE: Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=186, Not yet recruiting, Sponsor: Assistance Publique - H
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer (clinicaltrials.gov) - Aug 27, 2012
P2, N=41, Active, not recruiting, Sponsor: Hoosier Oncology Group
Recruiting --> Active, not recruiting Terminated --> Active, not recruiting
- || Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed: Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 21, 2012
P1, N=240, Active, not recruiting, Sponsor: Boehringer Ingelheim
Terminated --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: An Observational Study of Erbitux (clinicaltrials.gov) - Aug 21, 2012
P=N/A, N=146, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan (clinicaltrials.gov) - Aug 20, 2012
P2, N=20, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; former PI left institute
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan (clinicaltrials.gov) - Aug 20, 2012
P2, N=20, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Terminated; former PI left institute N=36 --> 20
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: ECHO-07: Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=42, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
N=36 --> 20 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=61, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial initiation date, Metastases: ERBITUX (clinicaltrials.gov) - Aug 13, 2012
P2, N=40, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Initiation date: Nov 2010 --> Feb 2011
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open, Metastases: ERBITUX (clinicaltrials.gov) - Aug 13, 2012
P2, N=40, Recruiting, Sponsor: University of Pittsburgh
Initiation date: Nov 2010 --> Feb 2011 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Metastases: Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=36, Recruiting, Sponsor: University of Michigan Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Surgery: Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=9, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery: Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=9, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated N=12 --> 9
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: KRDI-TUM-OE7-432-LOR-0033-I: Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer (clinicaltrials.gov) - Aug 6, 2012
P1/2, N=43, Active, not recruiting, Sponsor: Technische Universit
N=12 --> 9 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer (clinicaltrials.gov) - Aug 5, 2012
P2, N=6, Terminated, Sponsor: University of Kansas
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Study was stopped due to termination of funding
- ||| duligotuzumab (MEHD7945A) / Roche
Trial initiation date, Metastases: A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck (clinicaltrials.gov) - Aug 2, 2012
P2, N=122, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Terminated; Study was stopped due to termination of funding Initiation date: Apr 2012 --> Jul 2012
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Cetuximab and Carbo for ER/PR/HER2 Negative BC (clinicaltrials.gov) - Aug 2, 2012
P2, N=11, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Apr 2012 --> Jul 2012 N=100 --> 11
- |||| cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck (clinicaltrials.gov) - Aug 2, 2012
P2, N=91, Completed, Sponsor: ImClone LLC
N=100 --> 11 Active, not recruiting --> Completed